Auauniversity

Co-Host: Alexander Kutikov, MD, FACS At the conclusion of these activities, participants will be able to: 1. Discuss the evolving landscape of adjuvant therapy for the treatment of RCC. 2. Identify best practices for risk assessment and patient selection for adjuvant RCC therapy. 3. Differentiate the roles of urologist and medical oncologist in the care of patients with RCC. CME Available: auau.auanet.org/node/26087 This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma

Co-Host: Alicia K. Morgans, MD, MPH At the conclusion of these activities, participants will be able to: 1. Recognize cardiovascular comorbidities and describe their management in the context of prostate cancer treatment. 2. Differentiate the roles of the urologist, other specialists and primary care providers in the care of patients with prostate cancer. CME Available: https://auau.auanet.org/node/26059 This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma

Co-Host: Brian Shuch, MD At the conclusion of these activities, participants will be able to: 1. State the criteria for genetic testing of prostate cancer patients, the gene panels available, and options for testing these men. 2. Describe results of genetic testing and relay this information to patients in order to facilitate shared-decision making based on the test results. 3. Explain the importance of testing for germline mutations and their implication for novel therapies such as PARP inhibitors. CME Available: https://auau.auanet.org/node/26054 This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma

Co-Host: Vitaly Margulis, MD At the conclusion of these activities, participants will be able to: 1. Identify new technologies for the treatment of urothelial carcinoma and analyze the risks and benefits of treatment. 2. Facilitate discussions with patients and caregivers regarding of urothelial carcinoma treatment options. CME Available: https://auau.auanet.org/node/26079 This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma

The American Urological Association (AUA) and Società Italiana di Urologia (SIU) have collaborated to develop an independent educational activity to review the latest updates in immuno-oncology. This one hour course is designed to improve clinicians’ understanding of current immunotherapeutic agents for the treatment of GU cancers, improve patient outcomes, and the management of adverse events. The course covers the following topics: Immuno-Oncology: A Focus on Kidney Cancer Immuno-Oncology: A Focus on Bladder Cancer Immuno-Oncology: A Focus on Prostate Cancer Managing Immune-Related Adverse Events ACKNOWLEDGEMENTS Independent educational grant support for the webcast and podcast provided by Merck & Co., Inc., Kenilworth, NJ, US CME Available: https://auau.auanet.org/content/therapeutic-advances-immuno-oncology-2019

Co-Host: William Huang, MD At the conclusion of these activities, participants will be able to: 1. Discuss the current immunotherapy options available for the treatment of RCC. 2. Describe both completed and accruing clinical trials that are defining the paradigms of immunotherapy use in RCC. 3. Identify and manage the adverse events related to these agents. CME Available: auau.auanet.org/node/26095 This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma

Take Home Messages: Female Urology/Incontinence Ariana Smith, MD University of Pennsylvania Take Home Messages: Reconstruction Giulia Lane, MD Urology Fellow, FPMRS University of Michigan

Co-Host: Maxwell Meng, MD At the conclusion of these activities, participants will be able to: 1. Identify treatments for non-metastatic and metastatic CRPC and describe the proper order for their administration. 2. Manage nm and mCRPC with systemic agents by learning the proper candidates for treatment and be able to counsel patients on the pros and cons of therapy. 3. Review the newer generation antiandrogen agents and their use in nmCRPC and in mCRPC. CME Available: auau.auanet.org/node/26067 This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma

Co-Host: Robert Svatek, MD At the conclusion of these activities, participants will be able to: 1. Recognize both historic and newer immunotherapy options in the treatment of bladder cancer. 2. Describe the mechanism of action of immunotherapy regimens. 3. Identify and manage the adverse events related to these agents. CME Available: auau.auanet.org/node/26071 This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma

Co-Host: Kelvin Moses, MD At the conclusion of these activities, participants will be able to: 1. Identify the active agents and their mechanism of action in the management of metastatic HSPC. 2. Describe the risks and benefits of treatment for metastatic HSPC. CME Available: auau.auanet.org/node/26063 This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma

Please enjoy this free lesson of the AUA Update Series Volume 38 Lesson 1: Diagnosis and Management of Pheochromocytoma Please send any comments to education@auanet.org

Co-Host: Yair Lotan, MD At the conclusion of these activities, participants will be able to: 1. Explain the scientific rationale for investigating immune oncology agents for BCG unresponsive disease and describe current clinical trial designs. 2. List both completed and accruing clinical trials that are defining the paradigms of chemotherapy and immunotherapy use in genitourinary malignancies. CME Available: auau.auanet.org/node/26083 This educational series is supported by independent educational grants from: Amgen Astellas AstraZeneca Bristol-Myers Squibb Genomic Health Merck Pfizer, Inc. Sanofi Genzyme UroGen Pharma

Take Home Messages in Pediatrics: Mark Faasse, MD MPH

Take Home Messages: Infertility/Andrology Sarah Vij, MD Cleveland Clinic Foundation Take Home Messages: Sexual Dysfunction Faysal Yafi, MD University of California Irvine

Take Home Messages in Endourology/Stones and Transplantation Endourology/Stones: Nishant Patel, MD UCLA Health System Transplantation: Nicholas Cowan, MD Urologist, Transplant surgeon Virginia Mason Medical Center

Take Home Messages: Basic Science (Benign) Travis Jerde, PHD Associate Professor of Pharmacology and Toxicology Indiana University School of Medicine Take Home Messages: Basic Science (Malignant) Donald Vander Griend, PhD Associate Professor The University of Illinois at Chicago

Moderator(s) A. Lenore Ackerman, MD Cedars-Sinai Medical Center Panelist(s) Toby Chai, MD Professor Yale University School of Medicine Duane Hickling, MD The Ottawa Hospital, The Ottawa Research Institute Kimberly Kenton, MD MD, MS Northwestern Ann Stapleton, MD Professor of Medicine University of Washington Jennifer Anger, MD, MPH Cedars-Sinai Medical Center

Support provided by independent educational grants from AstraZeneca, Bristol-Myers Squibb, Genentech and Merck CME Available: https://auau.auanet.org/node/25249 This course will review the most recent AUA practice guidelines for non-muscle-invasive bladder cancer and detail strategies to manage common clinical predicaments involved in the management of these tumors. Specifically we will review: the AUA guidelines; risk stratification and use of cystectomy; selection of the optimal intravesical agent at the right schedule; and treatment of toxicity from intravesical therapy. Practical solutions will be presented that can be readily integrated into the office setting. Emphasis is placed on the evaluation of real clinical cases with open audience participation.

This educational series is supported by independent educational grants from: AbbVie, Astellas and Pfizer, Inc., AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Genomic Health, Merck, Sanofi Genzyme Episode 3: Manipulating the Androgen Axis: Androgen Biosynthesis Inhibitors and Androgen Receptor Signaling Agents and Radionuclide Therapy and Bone Health Manipulating the Androgen Axis: Androgen Biosynthesis Inhibitors and Androgen Receptor Signaling Agents David F. Jarrard, MD Radionuclide Therapy and Bone Health Steve Boorjian, MD CME Available: auau.auanet.org/node/25405 The AUA is launching an educational initiative to focus on resident and fellow training in the area of Advanced and Castration-Resistant Prostate Cancer. Based on the documented need for additional education in this area, the AUA in collaboration with Society of Urologic Oncology (SUO) has developed multiple educational interventions to improve the ability to care for patients with CRPC. These educational activities may also be of in

Support provided by independent educational grants from AbbVie, Amgen, Astellas, AstraZeneca, Bristol-Myers Squibb, Genomic Health, Genentech, Merck, Pfizer, Inc. and Sanofi Genzyme CME Available: https://auau.auanet.org/content/novel-agents-concepts-management-hormone-na%C3%AFve-castrate-resistant-prostate-cancer-webcast-0 This course will include short didactic lectures followed by case presentations to give attendees an understanding of the many new FDA-approved agents, as well as existing standard therapies, for advanced prostate cancer-both non-metastatic and metastatic CRPC. Particular attention will be devoted to sequencing the new agents and positioning them as compared to older existing therapies. The cost effectiveness of new and existing agents will also be addressed. Learning Objectives: Diagnose both non-metastatic and metastatic castrate resistant prostate cancer (nmCRPC, mCRPC) and have a working knowledge of treatments and the proper order for administration. Manage nm and mCRPC with syst